XW043FBIntroduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11
- Billable / Specific Code
XW043FB is a billable ICD-10-PCS procedure code for Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration of therapeutic substances, NEC.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 4 | Central Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | F | Valoctocogene Roxaparvovec-rvox |
| 7 | Qualifier | B | New Technology Group 11 |
In the ICD-10-PCS Alphabetic Index
These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:
Clinical Classification (CCSR)
AHRQ groups this procedure code into these clinical categories.
Code History
- 3E043GC — Introduce Oth Therap Subst in Central Vein, Perc
Similar Procedure Codes
Questions About XW043FB
Is XW043FB a billable code?
Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11 on inpatient claims from October 1, 2026 through September 30, 2027.
What do the characters in XW043FB mean?
The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character F is the Device/Substance/Technology (Valoctocogene Roxaparvovec-rvox); the 7th character B is the Qualifier (New Technology Group 11).
What MS-DRG does XW043FB group to?
On an inpatient stay, Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.
